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Aim: The zinc finger antiviral protein (ZAP) is a mammalian host restriction factor, and it could inhibit HBV RNA
synthesis in vitro experiments. However, the role of ZAP against HBV in vivo environment is unclear. This study
aimed to investigate whether ZAP could act against HBV transcription and replication in ZAP tansgenic mouse
model.
Methods: HBV-replication-competent plasmid pHBV4.1 was transferred to ZAP transgenic ICR mouse via the tail
vein using a hydrodynamic in vivo transfection procedure, and ICR mouse were used as controls. HBV RNA and HBV
DNA replication intermediates in the liver were respectively analyzed by Northern blotting and Southern blotting.
The expression of hepatitis B surface antigen (HBsAg) and hepatitis B core antigen (HBcAg) in the liver tissue was
detected by immunohistochemical staining.
Results: As compared to ICR control mouse, the levels of 3.5 kb mRNA in ZAP transgenic mouse were decreased
by 8.4%; while the level of HBV DNA replication intermediates was decreased by 82%. In addition, the expression of
HBsAg and HBcAg in ZAP transgenic mouse liver were both significantly less than that of ICR control mouse.
Conclusions: Our findings suggest that ZAP could inhibit HBV replication in vivo in mice, which offers a new target
for anti-HBV drug development.
Keywords: Zinc-finger antiviral protein, Hepatitis B virus, Transgenic mouse, Transcription and replicationBackground
Hepatitis B virus (HBV) infection is a serious global public
health problem, and approximately two billion people who
have been infected worldwide. Of them, there are more
than 350 million who are chronic carriers of HBV [1,2].
Sufficient evidences have showed that the level of serum
HBV DNA is a strong predictor of HBV-related compli-
cations [3]. And how to effectively control and even
eliminate virus replication has been concerned increasingly
by clinicians [4,5].
In past decades, five oral nucleos(t)ide analogues (NAs)
are approved for the treatment of chronic HBV infection
[6-8], which decrease virus production by inhibiting
the HBV DNA polymerase. However, because of the* Correspondence: htang6198@hotmail.com
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unless otherwise stated.persistence of HBV covalently closed circular (cccDNA) in
liver, current NAs treatment rarely eradicate HBV infec-
tion, and most patients require long-term NAs administra-
tion. Recently, with the extension of duration of treatment,
the issues of drug resistance, viral relapse and particularly
suboptimal response to current antiviral agents are increas-
ingly evident [9-12], and how to manage those patients
after initial therapy failure has become the primary concern
for clinicians [5]. So the development of the effective drugs
that target different stages of life cycle of HBV is still
needed.
The zinc finger antiviral protein (ZAP) is a mammalian
host restriction factor. Though ZAP itself does not have
RNase activity, it could bind to viral RNA specific se-
quences and recruite the exosome to degrade the target
RNA substrate [13]. For example, ZAP can specially
inhibit the replication of murine leukemia virus (MLV),
xenotropic murine leukemia virus-related virus (XMRV),his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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type 1(HIV-1), ebola virus, marburg virus [15-17] and so
on. Indeed, the inhibition activity of ZAP is not just re-
stricted to positive-strand RNA viruses, and retroviruses are
also targets of ZAP. One recent in vitro study has shown
that ZAP also plays a role in the innate control of HBV
replication, through down-regulation of viral RNA [18].
However, it is still unclear whether in vivo and in vitro
environments have different effects on ZAP against HBV,
because ZAP does not induce a universal antiviral state and
some viruses could replicate normally in ZAP-expressing
cells [19]. To clarify the effect of ZAP against HBV in vivo
environment, present study was designed to evaluate the ef-
ficacy of ZAP against HBV transcription and replication in
ZAP tansgenic mouse model.
Materials and methods
Plasmids
The plasmid pHBV4.1(ayw subtype), which contains 1.3
copies of the HBV genome, includes the viral sequence
from nucleotide coordinates 1072 to 3182 plus 1 to 1990.
This construct has been proven to initiate replication of
HBV efficiently after being transfected into human hepa-
toma HepG2 cell lines [20,21]. The plasmid pEFmZAPmyc
was a ZAP expression plasmid, which was constructed by
integration of mZAPmyc fragment into the plasmid pEF/
myc/nuc/GFP (Invitrogen).
The ZAP transgenic mouse and HBV replication mouse
model
All mice used in this study were breeded at specific-
pathogen-free (SPF) level, weighing 22-24 g. The ZAP
transgenic mouse and ICR mouse were provided by Center
for Infections and Immunity, Institute of Biophysics,
Chinese Academy of Sciences, Beijing, China. For con-
struction of the transgenic mouse, the plasmid pEFm-
ZAPmyc was injected into the fertilized egg nucleus of
ICR mouse by microinjection, transferred into uterine
tube of the fake pregnant female mouse and identified
successfully.
In order to establish the mouse model for HBV replica-
tion, 10 μg of pHBV4.1 plasmids diluted in phosphate-
buffered saline (PBS) was injected into the mouse tail vein
in a volume of 10% of the body weight (v/w) within 5-8
seconds (hydrodynamic in vivo transfection) [22]. ZAP
transgenic mouse transfected pHBV4.1 was termed the
ZAP-ICR/HBV mouse as experimental group, and ICR
mouse transfected pHBV4.1 was termed ICR/HBV mouse
as control group. All mice were sacrificed after 3 days of
pHBV4.1 injection and liver tissues were collected.
Analysis of HBV RNA in mice liver by Northern blotting
Frozen mice liver tissue mechanically pulverized in liquid
nitrogen were processed for RNA extraction using Trizolreagent (Invitrogen, USA) following the manufacturer’s
instructions. The 30 μg total HBV RNA was analysed
by Northern blotting hybridization and probed for both
digoxigenin-labeled (Roche, Swiss) GAPDH and HBV, as
previously described [23]. After electrophoresis, transfer,
UV cross-linking, prehybridization, hybridization, washing
and chromogenic reaction, the membranes were exposed
using Kodak RX films (Eastman Kodak Co, USA) for 0.5-1
hour at 37°C.
Analysis of HBV DNA replication intermediates in mice
liver by Southern blotting
Frozen liver tissues were mechanically pulverized in liquid
nitrogen and HBV DNA replication intermediates were
isolated from 120 μg liver tissue powders as described pre-
viously. All isolated of HBV DNA replication intermedi-
ates were diluted to 30 μL with TE buffer and then were
analyzed by DNA Southern blotting as previously de-
scribed. Membranes were hybridized with digoxigenin-
labeled (Roche Applied Science) HBV ayw genomic DNA
to detect HBV sequences. The levels of HBV DNA replica-
tion intermediates were calculated by the Quantity One
software according to manufacturer’s instructions (Bio-Rad,
USA).
Detection of HBsAg and HBcAg in mice liver by
immunohistochemical staining
The number and location of cells in the liver that expressed
HBsAg or HBcAg were assessed by immunohistochemical
staining. Liver tissue fixed in formalin was embedded
with paraffin and sectioned (3 mm thick). The paraffin-
embedded sections in PBS were treated for 15 min at
37°C with 30 g/L hydrogen peroxide, and washed with
PBS. After the sections were blocked with normal goat
serum for 20 min at 37°C, mouse anti-HBsAg (Thermol)
or rabbit anti-HBc (NEOMARKERS) primary antibody
was applied at 1:100 or 1:150 dilutions for 60 min at 37°C,
or overnight at 4°C, respectively. After washing with PBS,
the secondary antiserum consisting of Polymer-HRP Anti-
Rabbit (Zhongshan, Beijing) was applied at 1:350 dilutions
for 50 min at 37°C, according to the manufacturer’s in-
structions. The antibody-coated sections were washed
with PBS, stained with 3′, 3′-diaminobenzidine tetrahy-
drochloride (DAB), and counterstained with hematoxylin,
before being mounted.
Results
The effect of ZAP on HBV transcription and replication
In present study, the 3.5 kb mRNA and 2.4/2.1 kb
mRNA of HBV were detected in both ZAP transgenic
mouse and control mouse (Figure 1A). As compared to
control mice, the levels of 3.5 kb mRNA in ZAP trans-
genic mouse were decreased by 8.4% (Figure 1B); while
Figure 1 The transcription levels of HBV RNA in mouse liver tissue. (A): Lanes 1-5 for ICR control mouse and lanes 6-10 for ZAP transgenic
mouse. (B): Quantitative analysis results of the 3.5-kb HBV mRNA. (C): Quantitative analysis results of the 2.4/2.1-kb HBV mRNA. The mean value of
ICR control mouse was defined as 1, and GAPDH was used as internal control.
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were decreased by 21.1% (Figure 1C).
As shown in Figure 2, either the levels of HBV RC
DNA or HBV SS DNA in ZAP transgenic mouse were
decreased significantly than that in control mouse
(Figure 2A). As compared to control mouse, the levels
of HBV DNA replicative intermediate in ZAP transgenic
mouse were dereased by 82% (Figure 2B).
The effect of ZAP on HBsAg and HBcAg expression
As shown in Figure 3 (A-D), the staining of HBsAg was
presented as brown in the cytoplasm. There were only
very few HBsAg-positive cells in liver tissue of ZAP trans-
genic mouse(C and D); while HBsAg-positive hepatocytes
were abundant in liver tissue of control mouse(A and B).
As shown in Figure 3 (E-H), the staining of HBcAg was
presented as brown in the nuclei and cytoplasm. The
number of HBcAg-positive cells in ZAP transgenic mouse
(G and H) was significantly less than that in control
mouse(E and F), and the intensity of HBcAg-staining in
ZAP transgenic mouse was also weaker than that in con-
trol mouse.
Discussion
Recently, it has been reported that ZAP could inhibit a
variety of viruses replication, through interaction with the
ZAP-responsive elements (ZRE) in viral RNA and recruit-
ing the exosome to degrade RNA substrate [17,24]. Inspite of these achievements made, there are still inadequa-
cies in the full biological characteristics of ZAP. Because
all studies about the antiviral effect of ZAP are at cell level
in vitro, and there is no report about ZAP against HBV
in vivo environment. To our knowledge, either the virol/
host proteins or their interactions in regulating HBV
replication would be influenced by the types of cells and
microenvironment change [21,25]. So, it is necessary and
important to investigate the role of ZAP against HBV
in vivo models. The major findings in ZAP transgenic
mouse from present study are: (1) a slight decreasing
of HBV RNA, (2) a significant decreasing of HBV DNA
replication intermediates, (3) decreasing of viral proteins
expression.
As we know, host ZAP could be naturally expressed in
both ICR mouse and human body, but its expression
level is very low, which restricts the research progress of
ZAP against HBV to a certain degree. At present, there
are two widely used methods to induce target protein
expression in vivo, which include plasmid transfection
and transgene expression. As compared to conventional
plasmid transfection, transgene expression method is easy
to obtain a stable expression of target genes. With kind as-
sistance from Porf. Gao GX and his research team, who
had huge achievements on ZAP discovery and biological
functional study [24,26-28], we obtained a ZAP transgenic
mouse (data unshown in present study). For simulating an
in vivo environment with relative high ZAP expression
Figure 2 The replication levels of HBV DNA in mouse liver tissue. (A): Lanes 1-5 for ICR mice and lanes 6-10 for ZAP transgenic mouse. (B):
Quantitative analysis results of the relative intensity of HBV DNA replication intermediates. The mean value of ICR control mouse was set to 1.
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was subsquently delivered to this ZAP transgenic mouse
liver via tail vein injection. Previous study had found that
the HBV DNA replication intermediates in this mouse
model were abundant on day 3 and 4, and disappeared on
day 10 [29], thus day 3 after transfection was a widely used
timepoint to evaluate the change of HBV transcription
and replication levels [30,31]. Based on the previous re-
search experience, the role of host ZAP against HBV
transcription and replication in present study was also
evaluated at this timepoint.
It has been revealed that 3.5 kb mRNA contains all
genetic information of HBV DNA and plays a very im-
portant role in the life cycle of HBV as the template ofFigure 3 Immunohistochemical staining of HBsAg (A-D) and HBcAg (Ereplication. So in present study, the level of 3.5 kb mRNA
was used to reflect the transcriptional level of HBV in
both ZAP transgenic mouse and control mouse. In the
study reported by Prof. Mao and his colleague showed that
overexpression of ZAP could efficiently reduce HBV RNA
in cell cultures [18]. In present study, we also observed a
decreasing of 3.5 kb HBV mRNA as well as 2.4/2.1 kb
HBV mRNA in ZAP transgenic mosue in vivo. Though
the extent of 3.5 kb HBV mRNA decline was not obvious
in ZAP transgenic mosue, this finding was still consistent
with previous reports [18], because both in vivo and
in vitro experiments indicated a tendency of HBV RNA
dropping. Though ZAP-responsive element was mapped
in terminal redundant region (nt 1820–1918) of HBV-H) in liver tissue sections.
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bility of HBV RNA transcription templates, because the
activities of HBV core as well as S1 and S2 promoters
was not significantly affected by ZAP [18]. So there was
an inference that ZAP-mediated HBV RNA reduction
was not due to a transcriptional inhibition, but rather
through accelerating HBV RNA decay [18]. Considering
the less decreasing of 3.5 kb HBV mRNA in vivo than
in vitro, we speculated the process of ZAP recruiting
the RNA processing exosome to degrade HBV RNA may
be influenced in ZAP transgenic mouse by some unknown
factors, and the changes between in vitro and in vivo en-
vironment may be associated with it. And future studies
are strongly required to confirm this speculation.
In preset study, the significant decline of HBV DNA
replication intermediates in ZAP transgenic mouse was
consistent with previous findings in vitro experiment. At
present, it was well-known in vitro experiment that ZAP
inhibited HBV replication through posttranscriptional
down-regulation of viral pgRNA [18]. To our knowledge,
many evidences had suggested that in vivo very subtle
changes in HBV transcription may contribute to large al-
terations, either negative or positive, in viral replication
[32]. So we believed that the significant decline of HBV
DNA replication intermediates in ZAP transgenic mouse
should be explained by above mentioned HBV RNA
decay. Additionally, the expression of HBsAg and HBcAg
were also inhibited in ZAP transgenic mouse in present
study. We thought the significantly decline of HBV DNA
replication intermediates should be the main cause of the
inhibition of virol protein expression.
In summary, present study firstly investigate the effect
of ZAP against HBV transcription and replication in vivo
environment, and the results suggest that ZAP can also ef-
fectively inhibit HBV replication. This finding will offer a
new potential target for anti-HBV drug development.
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